In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:WHO Global Clinical Platform: COVID-19 outcomes in PWH2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)Investigational antiretroviral useCAB LA + RPV LA in treatment-naive PWH (FLAIR)Investigational antiretroviral agentsLEN (CAPELLA, CALIBRATE)ISL (P011, P016)Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.Follow along with an expanded slideset at: https://bit.ly/3syWD5TLink to full program: https://bit.ly/3z8SBnC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related